

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Bloomage BioTechnology Corporation Limited

華熙生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 00963)

**VOLUNTARY ANNOUNCEMENT
COMPLETION OF THE ACQUISITION**

Reference is made to the announcement (the “**Announcement**”) of Bloomage BioTechnology Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 6 January 2017 relating to the acquisition of shares representing the entire issued share capital of Revitacare, a *société par actions simplifiée* incorporated in France. Unless otherwise specified, capitalised terms used herein shall have the same meanings as that defined in the Announcement.

The Board is pleased to announce that the Condition for Completion has been satisfied as at 19 January 2017 and that pursuant to the Sale and Purchase Agreement, the Acquisition was successfully completed on 19 January 2017.

By order of the Board
Bloomage BioTechnology Corporation Limited
Zhao Yan
Chairman

Hong Kong, 19 January 2017

As at the date of this announcement, the executive Directors are Ms. Zhao Yan, Mr. Jin Xuekun, Mr. Gong Anmin and Ms. Wang Aihua; the non-executive Director is Mr. Yau Wai Yan; the independent non-executive Directors are Ms. Zhan Lili, Mr. Li Junhong and Mr. Xue Zhaofeng.